AngioDynamics introduces redesigned Centros self-centering chronic hemodialysis access catheter

AngioDynamics (NASDAQ:ANGO) announced today it has achieved the national launch of the newly redesigned Centros self-centering, chronic hemodialysis access catheter.

“The Centros self-centering hemodialysis catheter represents a significant improvement over other products currently available in its class”

The Centros hemodialysis access catheter employs Curved Tip™ Catheter Technology that is designed to provide higher blood flow and lower recirculation. When it is placed in the lower portion of the superior vena cava, the Centros catheter's curved tips keep the ports of the catheter centered, away from the vein walls. This is intended to prevent clots from forming or fibrin sheathing in which a fibrous protein in the blood coats the catheter, eventually closing up the openings and compromising its function. The Centros catheter design features also include an improved, lower-profile fiber cuff to maximize tissue ingrowth for anchoring and for ease of removal.

"The Centros self-centering hemodialysis catheter represents a significant improvement over other products currently available in its class," said Robert Rossell, Senior Vice President and General Manager of AngioDynamics' Vascular Access Business Unit. "The Centros catheter meets an important clinical need and with the new design features we believe this catheter will provide physicians and patients with a tool designed for faster procedures requiring fewer interventions and greater overall performance."

The Centros catheter owes its key design elements to Stephen R. Ash, MD, FACP, a world renowned thought leader in the field of hemodialysis access. Preliminary study results presented by Dr. Ash indicate that the Centros catheter provides highly acceptable flow rates at modest negative pressure without deterioration in flow rate over seven weeks of use, even with tips positioned in the superior vena cava rather than within the atrium. Flow rate for the Centros catheter at the seven week follow-up point was 401mL/min, compared to the control group of competitive catheters at 348mL/min. (P value less than 0.05).

SOURCE AngioDynamics